Laurie Gaspar, MD, from the University of Colorado School of Medicine, discusses the potential of heat shock protein (HSP) inhibitors as radiation sensitizers.
Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the potential of heat shock protein (HSP) inhibitors as radiation sensitizers.
Currently, most of the research in this setting has been preclinical. Gaspar believes that this would be a promising area for HSP inhibitors, as they could be combined with a smaller dose of radiation, and consequently limit the side effects.
Gaspar says that the radiation-sensitizing potential of HSP inhibitors could exist in any cell, but may work best in radiation-resistant cells. This could be the right time to move this theory into the clinical setting for lung cancer.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More